Case Intel
- The Trump Administration cites mounting evidence that prenatal acetaminophen use is tied to autism and ADHD.
- Harvard, Johns Hopkins, and Mount Sinai studies highlight consistent risks across large-scale cohort data.
- Insurers face potential flood of litigation, new coverage disputes, and liability exposures tied to autism claims.
WASHINGTON, D.C. — President Donald J. Trump stood alongside administration officials today to announce what his team called “major progress in understanding the root causes of autism.” The White House, through Press Secretary Karoline Leavitt, unveiled new health guidance warning pregnant women about the risks of acetaminophen and simultaneously approved a new treatment option said to improve autism symptoms.
“The Trump Administration does not believe popping more pills is always the answer for better health,” Leavitt said in the September 22nd press briefing. “There is mounting evidence finding a connection between acetaminophen use during pregnancy and autism — and that’s why the Administration is courageously issuing this new health guidance… We will not be deterred in these efforts as we know millions across America are grateful.”
President Donald Trump and U.S. Health and Human Services Secretary Robert F. Kennedy Jr. publicly warned against taking products like Tylenol that contain acetaminophen during pregnancy.
“Taking Tylenol is not good. I’ll say it. It’s not good,” Trump said. “Ideally you don’t take it at all. … I think you shouldn’t take it. You shouldn’t take it during the entire pregnancy.”
The announcement has triggered predictable resistance from mainstream media outlets, which immediately cast doubt and attempted to downplay the evidence. But peer-reviewed research continues to mount, suggesting that prenatal exposure to acetaminophen may increase the risk of neurological disorders such as autism and ADHD.
